Drug firm Aurobindo Pharma on Tuesday said it has
received the US health regulator's final approval to market Abacavir Tablets, used in the treatment of Human Immunodeficiency Virus (HIV), in the American market.
Abacavir Tablets USP in strength of 300 mg
is the generic equivalent of ViiV Healthcare Company's Ziagen and is indicated as part of antiretroviral (ARV) combination therapy for the treatment of HIV-infected adults and children.
"The company has received final approval from the US Food and Drug Administration (USFDA) to manufacture and market the earlier tentatively approved Abacavir Tablets USP 300mg and is ready for launch,"
Aurobindo Pharma said in a filing to the Bombay Stock Exchange.
"The annual sale of the product is approximately $88 million. The product has been approved out of Unit III formulations facility in Hyderabad, India," the company said.
Aurobindo now has a total of 167 abbreviated new drug application (ANDA) approvals from the USFDA.
Shares of Aurobindo Pharma were trading at 2.09 per cent higher in late afternoon trade at Rs 190.95 on BSE.
With inputs from PTI 
Special 
